Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alberta Cancer Board |
---|---|
Information provided by: | Alberta Cancer Board |
ClinicalTrials.gov Identifier: | NCT00754078 |
The hypothesis is that helical tomotherapy could minimize radiation related toxicity by avoiding or limiting doses to structures such as small bowel, external genetalia, skin, bladder, rectum, and femoral neck and head.
Condition | Intervention | Phase |
---|---|---|
Anal Canal Cancer |
Radiation: Tomotherapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy |
Estimated Enrollment: | 37 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | September 2010 |
Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
anal cancer patients treated with tomotherapy and chemotherapy
|
Radiation: Tomotherapy
30 fractions of tomotherapy treatment
|
This is a phase II study using tomotherapy for radiation treatment delivery along with concurrent 5-FU/mitomycin C for the treatment of T2-T4 cancer of the anal canal. They hypothesis is that helical tomotherapy could minimize radiation related toxicity by avoiding or limiting doses to structures such as small bowel, external genitalia, skin, bladder, rectum, and femoral neck and head. This is expected to limit or reduce treatment related toxicity and hence prevent or reduce treatment breaks. This may result in delivery of radical treatment with better local control and treatment outcome than using the current radiation treatment technique at our center.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kurian J Josepth, MD, FRCPC | (780) 432 - 8755 | kurianjo@cancerboard.ab.ca |
Canada, Alberta | |
Cross Cancer Institute | |
Edmonton, Alberta, Canada, T6G 1Z2 |
Principal Investigator: | Kurian J Joseph, MD, FRCPC | Alberta Cancer Board |
Responsible Party: | Cross Cancer Institute ( Dr. Kurian J Joseph ) |
Study ID Numbers: | GI-24329 |
Study First Received: | September 15, 2008 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00754078 |
Health Authority: | Canada: Health Canada |
tomotherapy |
Quality of Life Carcinoma |